MA39175A1 - Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives - Google Patents

Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives

Info

Publication number
MA39175A1
MA39175A1 MA39175A MA39175A MA39175A1 MA 39175 A1 MA39175 A1 MA 39175A1 MA 39175 A MA39175 A MA 39175A MA 39175 A MA39175 A MA 39175A MA 39175 A1 MA39175 A1 MA 39175A1
Authority
MA
Morocco
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
MA39175A
Other languages
English (en)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39175A1 publication Critical patent/MA39175A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des formes pharmaceutiques solides comprenant la substance médicamenteuse 3- (2,6-dichloro -3,5-diméthoxy-phényl) -1- {6- [4- (4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin -4-yl} -1-méthyl-urée ou n'importe quel sel pharmaceutiquement acceptable de celle-ci. L'invention porte en outre sur des procédés de fabrication desdites formes pharmaceutiques solides.
MA39175A 2013-12-13 2014-12-11 Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives MA39175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (fr) 2013-12-13 2014-12-11 Formes pharmaceutiques

Publications (1)

Publication Number Publication Date
MA39175A1 true MA39175A1 (fr) 2017-10-31

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39175A MA39175A1 (fr) 2013-12-13 2014-12-11 Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives

Country Status (34)

Country Link
US (3) US10278969B2 (fr)
EP (2) EP3079667B1 (fr)
JP (2) JP6522619B2 (fr)
KR (1) KR102349893B1 (fr)
CN (2) CN116942629A (fr)
AR (1) AR098716A1 (fr)
AU (1) AU2014362999B2 (fr)
CA (1) CA2930055C (fr)
CL (1) CL2016001436A1 (fr)
CY (1) CY1122063T1 (fr)
DK (1) DK3079667T3 (fr)
EA (1) EA036288B1 (fr)
EC (1) ECSP16060194A (fr)
ES (1) ES2745983T3 (fr)
HK (1) HK1223833A1 (fr)
HR (1) HRP20191691T1 (fr)
HU (1) HUE045156T2 (fr)
IL (1) IL245705B (fr)
LT (1) LT3079667T (fr)
MA (1) MA39175A1 (fr)
MX (1) MX2016007652A (fr)
MY (1) MY194303A (fr)
NZ (2) NZ760002A (fr)
PE (1) PE20160851A1 (fr)
PH (1) PH12016501039A1 (fr)
PL (1) PL3079667T3 (fr)
PT (1) PT3079667T (fr)
RS (1) RS59270B1 (fr)
SG (1) SG10202104627UA (fr)
SI (1) SI3079667T1 (fr)
TN (1) TN2016000207A1 (fr)
TW (2) TWI721938B (fr)
WO (1) WO2015087283A1 (fr)
ZA (1) ZA201603064B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036288B1 (ru) 2013-12-13 2020-10-22 Новартис Аг Фармацевтические лекарственные формы
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2019046167A1 (fr) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
WO2022133212A1 (fr) * 2020-12-18 2022-06-23 Qed Therapeutics, Inc. Méthodes de traitement de l'achondroplasie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
ME00011A (fr) 2005-12-21 2009-02-10 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2726076B1 (fr) 2011-07-01 2016-10-12 Novartis AG Polythérapie
EP3019491A4 (fr) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc Inhibiteurs de kinase pour le traitement d'une maladie
EA036288B1 (ru) 2013-12-13 2020-10-22 Новартис Аг Фармацевтические лекарственные формы
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases

Also Published As

Publication number Publication date
PL3079667T3 (pl) 2020-02-28
TN2016000207A1 (en) 2017-10-06
PT3079667T (pt) 2019-10-10
JP2019142927A (ja) 2019-08-29
KR102349893B1 (ko) 2022-01-10
DK3079667T3 (da) 2019-09-09
NZ719865A (en) 2022-07-29
EP3597179A1 (fr) 2020-01-22
MX2016007652A (es) 2016-10-13
HUE045156T2 (hu) 2019-12-30
EP3597179B1 (fr) 2024-04-03
IL245705A0 (en) 2016-07-31
RS59270B1 (sr) 2019-10-31
SI3079667T1 (sl) 2019-10-30
AU2014362999A1 (en) 2016-05-26
WO2015087283A1 (fr) 2015-06-18
US20220265651A1 (en) 2022-08-25
TWI800759B (zh) 2023-05-01
HK1223833A1 (zh) 2017-08-11
NZ760002A (en) 2022-07-29
US20170007602A1 (en) 2017-01-12
ZA201603064B (en) 2017-07-26
AR098716A1 (es) 2016-06-08
CL2016001436A1 (es) 2017-02-10
LT3079667T (lt) 2019-09-10
CA2930055A1 (fr) 2015-06-18
EP3079667B1 (fr) 2019-06-26
EP3079667A1 (fr) 2016-10-19
CN116942629A (zh) 2023-10-27
AU2014362999B2 (en) 2017-10-12
US10278969B2 (en) 2019-05-07
SG10202104627UA (en) 2021-06-29
US11160804B2 (en) 2021-11-02
PH12016501039A1 (en) 2016-07-04
ES2745983T3 (es) 2020-03-04
TW201605494A (zh) 2016-02-16
CN105813635A (zh) 2016-07-27
TWI721938B (zh) 2021-03-21
CA2930055C (fr) 2023-07-04
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
JP2017502941A (ja) 2017-01-26
TW202128137A (zh) 2021-08-01
EA036288B1 (ru) 2020-10-22
CY1122063T1 (el) 2020-11-25
ECSP16060194A (es) 2019-07-31
EA201691231A1 (ru) 2016-10-31
KR20160096093A (ko) 2016-08-12
MY194303A (en) 2022-11-27
HRP20191691T1 (hr) 2019-12-27
JP6804585B2 (ja) 2020-12-23
JP6522619B2 (ja) 2019-05-29
IL245705B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
EA201100032A1 (ru) Соединения пиридина
BRPI0610187B8 (pt) tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA44759B1 (fr) Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
MA39175A1 (fr) Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
NZ728392A (en) High dosage strength tablets of rucaparib
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
WO2014081712A3 (fr) Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
MA39294A1 (fr) Polythérapie contre le cancer
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2023005875A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
NZ708802A (en) Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии